Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

    NEXT STORY
    India Plant Extract Market Analysis, 2018-2019 & 2023, Featuring Profiles on Dabur India, Emami, Patanjali, Arjuna Natural Extract Limited, Vidya Herbs, and More
    PREV STORY
    Houston Methodist (part of Texas Medical Center) to start patient enrollment for Biomerica’s InFoods® Irritable Bowel Syndrome (IBS) diagnostic guided therapy clinical trial
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab

    Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine ...

    author_avatar
    NASDAQ Market News

    Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose

    ALPHARETTA, Ga., Jan. 20, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company ...

    author_avatar
    NASDAQ Market News

    Seven Medical Societies Join the ACR to Oppose Insurer Policy Limiting Access to In-Office Treatments

    author_avatar
    NASDAQ Market News